Related Experiment Video

Updated: Feb 15, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.2K

[Platelet inhibition in patients with coronary, cerebral and peripheral macroangiopathy : What, when and how long?]

M Halbach1, S Baldus2

  • 1Klinik III für Innere Medizin, Herzzentrum, Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland. marcel.halbach@uk-koeln.de.

Der Internist
|January 18, 2018
PubMed

Insights

Platelet inhibition reduces vascular events in arterial diseases. This review provides evidence-based recommendations on antiplatelet therapy choices and durations for coronary, cerebral, and peripheral artery conditions.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Platelet aggregation inhibition is crucial for managing vascular events in patients with coronary artery disease, carotid artery stenosis, and peripheral arterial disease.
  • Treatment strategies, including monotherapy, combination therapy, and duration of dual platelet inhibition, are tailored to clinical scenarios and patient specifics.

Purpose of the Study:

  • To review current clinical trial data and guidelines on platelet inhibition for coronary, cerebral, and peripheral arterial diseases.
  • To provide evidence-based recommendations for antiplatelet therapy.

Main Methods:

  • Analysis of numerous randomized trials on platelet inhibition across various clinical settings.
  • Incorporation of recent European professional society guidelines for antiplatelet therapy.

Main Results:

  • Latest randomized trials and major society guidelines inform recommendations for antiplatelet strategies.
  • Specific recommendations are available for stable coronary artery disease, post-stent implantation, acute coronary syndromes, and cerebrovascular/peripheral arterial disease.

Conclusions:

  • Evidence-based recommendations for platelet inhibition can be formulated for diverse arterial diseases.
  • Optimal antiplatelet therapy selection and duration are critical for patient outcomes.
Abstract

Keywords:
Carotid stenosisCoronary artery diseasePeripheral arterial diseasePlatelet aggregation inhibitorsStroke

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.5K

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.4K
Coronary Circulation01:21

Coronary Circulation

The heart, an organ critical to survival, gets nourishment not from the blood it pumps but from a separate circulation system known as coronary circulation. This is the shortest circulation in the body and is responsible for supplying the heart with the nutrients it needs to function effectively.
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...
7.6K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.9K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
3.8K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
9.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K